Business Context and Reporting Period
Company: Alkermes Plc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 30, 2018
Reporting Period: Single event date (October 30, 2018)
This filing serves as a Regulation FD disclosure regarding the U.S. Food and Drug Administration (FDA) posting of briefing materials for an upcoming advisory committee meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding a specific event and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses exclusively on the regulatory status of a new drug application.
Guidance, Outlook, and Material Events
- Regulatory Event: The FDA posted briefing materials on October 30, 2018, for a joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.
- Meeting Date: November 1, 2018.
- Subject: Review of Alkermes plc's new drug application for ALKS 5461.
- Access: Briefing materials are available on the FDA website.
- Legal Disclaimer: The information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the outcome of the November 1, 2018, FDA advisory committee meeting regarding ALKS 5461.
- Review the specific FDA briefing materials linked in the filing for detailed clinical data and safety assessments.
- Monitor subsequent FDA communications for the final approval decision on the new drug application.
- Check for any future 8-K filings or press releases detailing the impact of the committee's recommendation on the company's pipeline.